Investorideas.com newswire, breaking biotechnology and pharma news

Tuesday, December 15, 2020

#AI/ #Health #Stock News: GBT Tokenize (OTCPINK: $GTCH) Post Completing Prototype for qTerm Further Research - Advanced Oxygen & Heart Rate Systems; @GbtTechnologies #Artificialintelligence

  

#AI/ #Health #Stock News: GBT Tokenize (OTCPINK: $GTCH) Post Completing Prototype for qTerm Further Research - Advanced Oxygen & Heart Rate Systems; @GbtTechnologies #Artificialintelligence

 


San Diego, CA, December 15, 2020 – (Investorideas.com Newswire) GBT Technologies Inc. (OTCPINK: GTCH("GBT”, or the “Company”), announced that its Joint Venture, GBT Tokenize Corp. (“GBT/Tokenize”), started research for advanced oxygen and heart rate systems for its qTerm medical device. The current qTerm oximeter is an optical based sensor system that measures the heart rate and oxygen levels, utilizing an electronic processor and a set of small light-emitting diodes (LEDs). The system uses light sources (LEDs) and a light detector to measure the variation in blood volume in tissues. The variation in the blood volume is used to determine the heart rate and the oxygen levels are measured based on blood cells color. Human blood appears red because of a protein called hemoglobin which contains a red-colored compound for carrying oxygen through the bloodstream.

 

Read this news, featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2020/12151Prototype-qTerm.asp

 

With a touch of a finger, beams of light measure the amount of oxygen in your blood by analyzing the color and movement of blood cells. Dark red blood cells indicate a lack of oxygen, while bright red blood cells indicate higher oxygen level. For example, if 96% of the blood cells are bright red, while 4% are dark red, then the Sp02 (Oxygen) level would be 96%. When a finger is placed on the qTerm device, a light source emits intense light. A light detector detects the light that passed through the finger, measuring how much was absorbed. A computer program performs an accurate calculation to produce numerical results. One of the main advantages of pulse and oxygen oximetry is the fact that it is a painless and noninvasive method. Oxygen saturation is an important measure to indicate proper functionality of our lungs. As we breath, our lungs pass oxygen into tiny blood vessels called capillaries. The capillaries transport oxygen-rich blood to our organs. The heart pumps the blood through arteries to the rest of the body to maintain constant supply of oxygen. In case of improper lung functionality, blood oxygen saturation declines, potentially putting our organs in danger. A pulse/oxygen oximeter can quickly detect a drop in oxygen saturation and alert for medical intervention.

 

GBT/Tokenize is now conducting further research for a faster and potentially less power consuming system to measure heart rate and blood oxygen levels. In this research different integrated circuits are considered along with additional circuitries. Two types of PPG (photoplethysmography - an optical measurement method that is used for heart rate and oxygen level monitoring using a light source and a photodetector at the surface of skin) will be evaluated, transmittance and reflectance. In transmittance PPG, the light source is placed on one side of the tissue, while the light detector is placed on the other side. This type of PPG can only be used in small volume organs and requires further mechanical infrastructure, like clamping devices and similar. In a reflectance type PPG, the light source and detector are both placed on the same side of the tissue. qTerm is a reflectance type based device. The source emits the light into the tissue and the detector measures the variation in the reflected light. This design type is less complicated and easy for use. This type of technology can be used over any part of the body. The research includes a platform for measuring the heart rate and blood oxygen to conduct further experiments and tests to optimize results. The research is targeted to prepare the next generation sensors and controlling circuits for future releases of qTerm.

 

"GBT/Tokenize R&D is constantly researching to improve and enhance the technology. As we are geared to release the first version of qTerm medical device soon, our research team is already seeking how to provide more advanced solutions for future releases. We consider qTerm as an evolutionary product that will continue to evolve, include additional features, provide faster results with less power consumption, we are already researching within a few domains in order to improve the product. Our research is focused on improving the device power management system, providing rapid results and creating new methods for data analysis. Another key feature is to keep the device's user friendliness, small size and ease of use. We are going to research methods of PPG (photoplethysmography) also to consider further vitals devices that could provide vitals measurements of any human organ surface. This may lead to the development of further devices of different shapes and characteristics. Since future versions of qTerm are planned to include blood pressure features we are researching new approaches and methods to enable optimal and accurate results. Another aspect is aesthetics, look and feel. We strongly believe that a device of this nature should be easy for use, with long battery life and attractive. As with any aspect of electronic devices, looks play a major role. For example, we all like gadgets and gizmos that simply look cool! It's our job to ensure reliable, accurate results within a 'cool' packaging. Last, but not least, a crucial factor is the product's cost. We keep in mind that the actual cost to the consumer has to be carefully considered. We are facing a constant challenge of providing high quality products that include the most up-to-date electronics, at an affordable cost. We are evaluating larger versions of the device for potential use in hospitals and clinics so we are looking into different enclosure's size and matching product's prices. An efficient R&D team must move forward at all times in order to constantly seek new technological solutions, research and develop better designs with higher performance for the user's benefit" stated Danny Rittman, GBT’s CTO.

 

Testing Advanced Oxygen & Heart Rate Systems:

 



Forward-Looking Statements 

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 


Get more tech stocks investor ideas- news, articles, podcasts and stock directories

 

 

 

 

 

 

 

 

Thursday, December 10, 2020

#AI #Health Breaking News: GBT Tokenize (OTCPINK: $GTCH) - qTerm's Prototype Completed; @GbtTechnologies #ArtficialIntelligence

 #AI #Health Breaking News: GBT Tokenize (OTCPINK: $GTCH) - qTerm's Prototype Completed; @GbtTechnologies #ArtficialIntelligence

 

GBT Technologies Inc. Enters Testing and Debugging Phase

 


SAN DIEGO - December 10, 2020 (Investorideas.com Newswire) GBT Technologies Inc. (OTCPINK: GTCH) ("GBT", or the "Company"), announced that its joint Venture GBT Tokenize Corp ("GBT/Tokenize") has completed its qTerm device prototype and is now in the testing and debugging phase. The testing and debugging phase is targeted to check the device's overall functionality and its sub-systems including BLE (Bluetooth Low Energy), IR heat sensors, oximeter sensors, power management and others. The initial testing provided satisfactory results and all electronic circuitries are fully functional.

 

Read this news featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2020/12101qTerm.asp

 

Further testing of the complete system will be conducted during the upcoming weeks in order to finalize the device’s functionality. Another aspect is the device's mechanical enclosure, components and sensors placement. The device is assembled based on the most up-to-date SMT (Surface Mount Technology). SMT is a method in which the electronic components (microchips, resistors, capacitors) are mounted directly onto the surface of a printed circuit board (PCB). SMT is an efficient method to create small electronic devices and to increase manufacturing automation which reduces cost and improves quality. It also allows for more electronic components to fit on a given area. qTerm prototype includes a PCB with IR and optical sensors, LEDs for visual feedback, battery and its enclosure. The device firmware, which is a permanent software code that is programmed into an internal read-only memory, provides the machine-level control for a device's specific hardware.

 

qTerm's embedded firmware provides a robust operating environment, performing functions control, monitoring and data manipulation operations. The device will be providing a visual feedback about the results, using colored LEDs and a mobile application information and alerts. A custom mobile application is working with the device to read the data, process it, and provide the results to the user. In addition, the mobile application is an interface to send data to a backend program that is running on a server. The data is planned to be further analyzed by AI algorithms to enable health monitoring, on-going health information and alerts. The mobile app is planned to use location information to provide proximity alerts in order to slow the pandemic spread. The proximity alerts will be based on voluntary, anonymous, private user's participation.

 

"Our qTerm vitals device prototype has been completed and now under intensive testing and debugging. We are excited to see its features coming alive," stated Danny Rittman, GBT’s CTO. "As with typical developments of this nature we encountered minor mechanical alignment issues due to the PCB fabrication. These were addressed in order to create an optimal mechanical support for the sensory systems. The really exciting news is that the electronics are 100% working according to the design. We are now testing each individual function of the device; among them are the Low Energy Bluetooth communication, the infrared heat sensors, the oximeter, which is the blood oxygen optical sensors, power consumption and others. We are also testing system level functions and features. We are focusing on evaluating each electrical and mechanical aspect, like sensor distances, accuracy, ease of use, and battery life. The PCB has been manufactured using SMT which enables smart, robust electronics within small areas. We embed the device's firmware and are now going through a sequence of functionalities testing and debugging. The firmware is a machine level program that is controlling qTerm's operations. The firmware is in charge of executing system level and active features. For example, measuring the ambient temperature as a reference is a system level function to be used for the purpose of proving an accurate active function of body heat measurement. In parallel we are testing the device connection with its mobile application via Bluetooth. The mobile application will provide numerical and statistics information based on the device's electronic results. The app is designed to send the data to a machine learning based backend program for further analysis. qTerm mobile app enables a voluntary, anonymous, proximity alert notification in order to help users and the community fight the pandemic spread. The app is designed to detect and alert in case another person, with the same app, and with elevated body temperature, is in proximity of 6 feet. The app will exchange a secure code with the other phone to record that they were near. Our AI technology will analyze the measurements results in order to identify potential health issues. In case of potential health issue detection, the system will alert the users in order to reduce the potential exposure risk to their families, friends, neighbors, co-workers and others. We put extra attention to the user's privacy and data protection. We are making all of our efforts to complete the testing as soon as possible in order to move to the full production of qTerm."

 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
GBT Technologies Inc.
Media: 
press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 


  Get more tech stocks investor ideas- news, articles, podcasts and stock directories

 

 

 

 

 

 

Friday, December 4, 2020

New #Stocks to Watch at Investor Ideas – Biotech (NASDAQ: $EVGN), Cannabis (CSE: $JUVA.C), Plant-Based Foods (CSE: $EATS.C) and CyberSecurity (NASDAQ: $TLS)

 

New #Stocks to Watch at Investor Ideas – Biotech (NASDAQ: $EVGN), Cannabis (CSE: $JUVA.C), Plant-Based Foods (CSE: $EATS.C) and CyberSecurity (NASDAQ: $TLS)

 


Point Roberts WA, Delta BC, December 4, 2020 – (Investorideas.com Newswire)
Investorideas.com, a global news source and leading retail investor and trader resource, announces its weekly roundup of stocks to watch in Biotech, Cannabis, Plant-Based Foods, CyberSecurity, Mining and China-Asia. Today’s stocks in have been added to our list of free stock directories in each sector.

 

Read this in full at https://www.investorideas.com/news/2020/main/12041Stocks.asp

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

 

The newest biotech companies are all life sciences companies and include recent Nasdaq IPOs.

 

The latest cannabis companies are both CSE listed, with Pure Extracts Technologies Corp. (CSE:PULL) crossing into functional mushrooms/psychedelics.

 

Also CSE-listed are the newest plant-based/vegan companies, along with the latest mining company.

 

The newest cybersecurity and China companies are both Nasdaq IPOS from November.

 

New Stocks added to Biotech stocks directory:

Evogene Ltd. (NasdaqGM:EVGN) is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production

 

Sotera Health Co (NasdaqGS:SHC) is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

 

MARAVAI LIFESCIENCES HOLDINGS, INC. (NasdaqGS:MRVI) is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases through its portfolio of companies and their proprietary capabilities and products. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

 

New Stocks added to Cannabis stocks directory:

Juva Life Inc. (CSE:JUVA) is a vertically-integrated cannabis company with deep roots in California cannabis culture and extensive expertise in all areas of cannabis production and sales, from cultivation through research and manufacturing to walk-in and delivery retail.

 

Pure Extracts Technologies Corp. (CSE:PULL) is an integrated Canadian plant-based extraction company specializing in the processing of cannabis, hemp and functional mushrooms to produce oils and various derivative products. The company is involved in white labeling activities as well as selling branded oil based products under the Pure Extracts brand. The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act

 

New Stocks added to Plant-based/Vegan stocks directory:

Eat Beyond Global Holdings Inc. (CSE:EATS) is an investment issuer that identifies and makes equity investments in global plant based protein companies that are developing and commercializing innovative food tech as well as alternative food products. The company provides retail investors with the unique opportunity to participate in the growth of a broad cross-section of opportunities in the alternative food sector, and access companies that are leading the charge toward a smarter, more secure food supply.

 

Plant & Co. Brands Ltd. (CSE:VEGN) formerly Euorlife Brands is a vertically integrated enterprise focused on the health and wellness sector. With a network of high-level contacts in the food and beverage industries across North America, South America and Europe, the executive team at EuroLife Brands is working toward a number of strategic partnerships to strengthen EuroLife’s offering of innovative plant-based food alternatives. Working diligently with their colleagues in the health and wellness industry, EuroLife plans to execute several joint ventures to bring together players from across various sectors to offer their strengths in creating a new and exciting lineup of plant-based foods for health-conscious consumers to enjoy. With deals already in place for plant-based beverages such as coffee and tea, EuroLife plans to move aggressively to expand its portfolio through mutually-beneficial partnerships, mergers, acquisitions, joint ventures and more.

 

New Stocks added to CyberSecurity stocks directory:

TELOS CORP (NasdaqGS:TLS) empowers and protects the world’s most security-conscious organizations with solutions for continuous security assurance of individuals, systems, and information. Telos’ offerings include cybersecurity solutions for IT risk management and information security; cloud security solutions to protect cloud-based assets and enable continuous compliance with industry and government security standards; and enterprise security solutions to ensure that personnel can work and collaborate securely and productively. The company serves military, intelligence and civilian agencies of the federal government, allied nations and commercial organizations around the world.

 

New Stocks added to Mining stocks directory:

Mosaic Minerals Corp. (CSE:MOC) (“Mosaic”) is a Canadian company whose principal business activity is the exploration, acquisition and development of mineral properties in Canada. Mosaic is currently focusing on the exploration and development of its recently acquired mineral property, the Opawica Project located south of Chibougamau in the province of Quebec, which is 100% owned by the company

 

New Stocks added to China-Asia stocks directory:

Yatsen Holding Ltd (NYSE:YSG) is a leader in the rapidly evolving China beauty market with the mission of creating an exciting new journey of beauty discovery for consumers in China and around the world. The Company has launched three fast-growing, successful color cosmetics and skincare brands: Perfect Diary, Little Ondine and Abby's Choice, and has recently acquired Galénic, an iconic premium skincare brand. Leveraging its digitally native direct-to-customer business model, the Company has built a platform with core capabilities that disrupt every part of the traditional beauty industry value chain and deliver greater value to its customers. The Company reaches and engages with customers directly both online and offline, with expansive presence across all major e-commerce, social and content platforms in China.

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news and press releases, research and our own original financial content. We were one of the first retail investor sites to cover renewable energy and cleantech stocks at investorideas.com and our domain Renewableenergystocks.com. We were also one of the most well- known and cited defense stock sites, featuring our domain Homelanddefensestocks.com at its peak.

We follow the money for investors as sector sentiment shifts and technology disrupts. Our mission is to provide investor ideas with breaking news, resources, industry articles and interviews with leading experts.      

 

Learn about investing in stocks and sector trends with our news alerts, articles,  podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto CornerPlay by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate ChangeExploring Mining and the AI Eye.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 

social-media ICONS.jpg

 

 

 

 

 

 

 

 

 

Wednesday, December 2, 2020

#MedTech #Stocks in the News: Sigyn Therapeutics (OTC: $SIGY) Reports Simultaneous Clearance of Endotoxin and Inflammatory Cytokines From Human Blood Plasma; @Sigyn_inc

 

#MedTech #Stocks in the News: Sigyn Therapeutics (OTC: $SIGY) Reports Simultaneous Clearance of Endotoxin and Inflammatory Cytokines From Human Blood Plasma; @Sigyn_inc

 

SAN DIEGO, CA, December 2, 2020 / -(Investorideas.com newswire) Breaking Medical Tech/ therapeutic technology stock news -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on treating life-threatening inflammatory conditions, today announced the completion of an in vitro study that demonstrated the ability of Sigyn Therapy™ to clear both endotoxin and inflammatory cytokines from human blood plasma. 

 

Read this news featuring SIGY in full at https://www.investorideas.com/news/2020/biotech/12021Sigyn-Therapeutics-Endotoxin-Cytokines.asp

 

Sigyn Therapy is a novel blood purification technology designed to mitigate cytokine storm syndrome, which precipitates a wide-range of life-threatening conditions, including sepsis, the most common cause of hospital deaths.  Virus induced cytokine storm syndrome is associated with high mortality and currently is a leading cause of SARS-CoV-2 (COVID-19) deaths.  Sigyn Therapy is a single-use device designed for use on the established infrastructure of dialysis and CRRT machines located in hospitals and clinics worldwide.

 

In the in vitro study, Sigyn Therapy simultaneously reduced the presence of endotoxin and relevant pro-inflammatory cytokines, which included Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a). Endotoxin (lipopolysaccharide or LPS) is a potent mediator implicated in the pathogenesis of sepsis and septic shock.  The dysregulated over-production of IL-1B, IL-6 and TNF-a can lead to organ failure and cause death.

 

An objective of the study was to rebalance elevated cytokine levels and optimize the elimination of endotoxin from human blood plasma. The study was conducted in triplicate over four-hour time periods with a pediatric version of Sigyn Therapy.  Average reduction of endotoxin load peaked at 83% during the studies. The average reduction of IL-1B was 69%, IL-6 reduction was 59% and TNF-a reduction was 57% during the four-hour studies.  The resulting data will be incorporated into an Investigational Device Exemption (IDE) that Sigyn plans to submit to the United States Food and Drug Administration (FDA) in 2021.

 

“The simultaneous clearance of endotoxin and inflammatory cytokines is a significant milestone that reinforces the potential of Sigyn Therapy to overcome the limitations of industry pioneering devices that are currently deployed to treat life-threatening inflammatory conditions,” stated Jim Joyce, Chairman and CEO of Sigyn Therapeutics.

 

At present, the CytoSorb device from CytoSorbents Corporation and the Toraymyxin device from Toray Industries are market cleared and broadly administered to treat a wide-range of life-threatening inflammatory conditions outside of the United States. In regards to mechanism, the Toraymyxin device has a high specificity to bind circulating endotoxin, but does not address inflammatory cytokines. Conversely, the CytoSorb device depletes inflammatory cytokines from circulation, but does not address endotoxin.

 

In addition to reporting the dual clearance of endotoxin and inflammatory cytokines, the Company further disclosed that it plans to evaluate the ability of Sigyn Therapy to address other inflammatory targets, including CytoVesicles that transport inflammatory cytokine cargos throughout the bloodstream.  The Company believes that Sigyn Therapy is the first therapeutic candidate to target circulating CytoVesicles.

 

About Sigyn Therapeutics

Sigyn Therapeutics™ is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

 

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

 

To learn more, visit www.SigynTherapeutics.com  or www.SigynTherapy.com

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.

 

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

jimjoyce@elevatescience.com

 

Investorideas.com Paid news Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure : this news release featuring (OTCMARKETS: SIGY) is a paid for news release on Investorideas.com  https://www.investorideas.com/News-Upload/ More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

 

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on Investorideas.com